Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure.
The molecular mechanisms underlying the transition from recreational drug use to chronic addiction remain poorly understood. One molecule implicated in this process is DeltaFosB, a transcription factor that accumulates in striatum after repeated drug exposure and mediates sensitized behavioral responses to psychostimulants and other drugs of abuse. The downstream transcriptional mechanisms by which DeltaFosB regulates drug-induced behaviors are incompletely understood. We reported previously the chromatin remodeling mechanisms by which DeltaFosB activates the expression of certain genes; however, the mechanisms underlying DeltaFosB-mediated gene repression remain unknown. Here, we identify c-fos, an immediate early gene rapidly induced in striatum after acute psychostimulant exposure, as a novel downstream target that is repressed chronically by DeltaFosB. We show that accumulation of DeltaFosB in striatum after chronic amphetamine treatment desensitizes c-fos mRNA induction to a subsequent drug dose. DeltaFosB desensitizes c-fos expression by recruiting histone deacetylase 1 (HDAC1) to the c-fos gene promoter, which, in turn, deacetylates surrounding histones and attenuates gene activity. Accordingly, local knock-out of HDAC1 in striatum abolishes amphetamine-induced desensitization of the c-fos gene. In concert, chronic amphetamine increases histone H3 methylation on the c-fos promoter, a chromatin modification also known to repress gene activity, as well as expression levels of the H3 histone methyltransferase, KMT1A (lysine methyltransferase 1A, formerly SUV39H1). This study reveals a novel epigenetic pathway through which DeltaFosB mediates distinct transcriptional programs that may ultimately alter behavioral plasticity to chronic amphetamine exposure.
Renthal
William
W
Department of Psychiatry and Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9070, USA.
Carle
Tiffany L
TL
Maze
Ian
I
Covington
Herbert E
HE
Truong
Hoang-Trang
HT
Alibhai
Imran
I
Kumar
Arvind
A
Montgomery
Rusty L
RL
Olson
Eric N
EN
Nestler
Eric J
EJ
D000661:Amphetamine / Q000008:administration & dosage*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004334:Drug Administration Schedule; D044127:Epigenesis, Genetic / Q000187:drug effects* / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D056284:Histone Deacetylase 1; D006655:Histone Deacetylases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D016716:PC12 Cells; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000502:physiology; D021381:Protein Transport / Q000187:drug effects / Q000235:genetics; D016760:Proto-Oncogene Proteins c-fos / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
C483819:Fosb protein, mouse; C483820:Fosb protein, rat; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D000661:Amphetamine; C515890:Hdac1 protein, rat; D056284:Histone Deacetylase 1; D006655:Histone Deacetylases